This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is ~~$(CH_2)_m[CH(R^1)]_n(CH_2)_p$~~ $(CH_2)_m(CH(R^1))_n(CH_2)_p$ ~~where;~~

n is 0 or 1~~; and;~~

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl ~~or~~ and heteroaryl groups ~~is~~ are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which ~~may be~~ is optionally substituted by aryl or heteroaryl, wherein the aryl ~~or~~ and heteroaryl groups ~~is~~ are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring ~~may contain~~ optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl ~~or~~ and heteroaryl groups ~~is~~ are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups ~~may be~~ are optionally interrupted by oxygen and wherein the phenyl groups ~~is~~ are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

provided that the compound is not:

~~i)~~ 2-[4-[5-(2,4-dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid.

2. (original) A compound according to claim 1 wherein Q is CH_2.

3. (currently amended) A compound according to claim 1 ~~or 2~~ wherein R^2 is hydrogen or halogen.

4. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxyl or C_{1-6} alkoxy, CF_3, OR^6, $NHCOR^8$ or $CONHR^9$, wherein at least one of R^3, R^4 and R^5 is other than hydrogen.

5. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 4 wherein one of R^3 and R^4 is $NHCOR^8$ and the other is hydrogen or halogen, and R^5 is hydrogen.

6. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which ~~may be~~ is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring ~~may contain~~ optionally contains up to two heteroatoms selected from NR^{12}, S and O; phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing ~~up~~ one to three heteroatoms selected from O, N and S, which heteroaryl group ~~may be~~ is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy or halogen.

7. (currently amended) A compound according to claim 6 wherein R^8 is C_{1-6} alkyl or C_{2-6} alkenyl, either of which ~~may be~~ is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing ~~up~~ one to three heteroatoms selected from O, N and S, which heteroaryl group ~~may be~~ is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy or halogen.

8. (currently amended) A compound according to claim 1 ~~of formula (I) as described in any one of Examples 1 to 24~~ selected from

2-[4-[5-(2,3-Dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[4-(2-Benzyloxyethylcarbamoyl)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-bistrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(2-methyl-3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-bromophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-methylenedioxophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(5-bromopyrindine-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-trifluoromethyl-4-fluorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-cyanophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(furan-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and

2-[4-[5-[2-Chloro-4-[3-(4-methoxy)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

or a pharmaceutically acceptable salt or prodrug thereof.

9. (currently amended) A compound according to claim 1 selected from:

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-ditrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

~~and~~ or a pharmaceutically acceptable ~~salts~~ salt ~~and~~ ~~prodrugs~~ or prodrug thereof.

10. (canceled)

11. (currently amended) A process for the preparation of a compound according to ~~any one of claims 1 to 9~~ claim 1 which comprises:

reacting a compound of formula (II):



(II)

~~wherein R^2, R^3, R^4 and R^5 are as defined in claim 1,~~ with a compound of formula (III):



(III)

wherein ~~Q is as defined in claim 1 and~~ R^A is H, C_{1-6} alkyl or a ~~suitable~~ protecting group; optionally followed~~, where required,~~ by deprotection of the group OR^A, to give the corresponding carboxylic acid.

12. (currently amended) A process for the preparation of a compound according to ~~any one of claims 1 to 9~~ claim 1 wherein one or more of R^3, R^4 and R^5 is $NHCOR^8$ which comprises:

reacting a compound of formula (VIII):



(VIII)

wherein one or more of R^3, R^4 and R^5 is NH_2, ~~R^2 and Q are as defined in claim 1~~ and R^A is ~~as defined in claim 11~~ H, C_{1-6} alkyl or a protecting group, with a compound of formula (IX):



(IX)

~~wherein R^8 is as defined in claim 1,~~ in an amide bond formation reaction.

13. (currently amended) A pharmaceutical ~~formulation~~ composition comprising a compound according to ~~any one of claims 1 to 9, without proviso i),~~ formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

together with a pharmaceutically acceptable carrier or excipient.

14-17. (canceled)

18. (currently amended) A compound of formula (II):.



(II)

wherein~~, R^2, R^3, R^4 and R^5 are as defined in claim 1~~

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

19. (currently amended) A compound of formula (X):



(X)

wherein ~~Q and R^2 are as defined in claim 1,~~

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^A is ~~as defined in claim 11~~ H, C_{1-6} alkyl, or a protecting group;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and

heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

provided that at least one of R^3, R^4 and R^5 is NO_2 ~~and the remainder are as defined in claim 1~~.

20. (new) A method for inhibiting heparanase activity in a patient suffering from a disease or disorder in which heparanase activity plays a role, comprising administering to the patient a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt of prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

21. (new) A method for the treatment of cancer comprising administering to a patient suffering from cancer a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

22. (new) The method of claim 21 wherein the cancer is melanoma, lymphoma, leukaemia, fibrosarcoma, rhabdomyosarcoma, mastocytoma, colorectal cancer, prostate cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, renal cancer, liver cancer, gastric cancer, bladder cancer, or ovarian cancer.

23. (new) A method for the treatment of angiogenesis, angiogenesis dependent diseases, inflammatory diseases, autoimmune diseases, or cardiovascular diseases, comprising administering to a patient suffering from such a disease or disorder a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

24. (new) The method of claim 23 wherein angiogenesis and angiogenesis dependent diseases are angiogenesis associated with the growth of solid tumors or retinopathy.

25. (new) The method of claim 23 wherein the inflammatory diseases are autoimmune disorders selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease and wound healing.

26. (new) The method of claim 23 wherein the autoimmune disease is multiple sclerosis.

27. (new) The method of claim 23 wherein the cardiovascular diseases are thromoembolic disease, arterial thrombosis or restenosis.